Association Between Glucagon-Like Peptide-1 Receptor Agonists and Risk of Arrhythmias.

ABSTRACT:

Background

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially designed to treat diabetes mellitus (DM), have demonstrated the potential to mitigate obesity-related cardiovascular risks. However, their effect on arrhythmias is not well established with limited literature.

Objective

This study aimed to assess the efficacy of GLP-1 RAs and the risk of cardiac arrest and arrhythmias in obese patients based on real-world evidence.

Methods

The TriNetX Global Collaborative Network research database was used to identify obese patients aged ≥ 18 years from January 2020 to December 2022. Patients were categorized into two groups, one with GLP-1 RAs and a control group without GLP-1 RAs. After propensity score matching (PSM), relative risk (RR) was used to compare

SUBMITTER: Jaiswal V 

PROVIDER: S-EPMC12704023 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature